Category Archives: TRIPS flexibilities

No logic in extending length of patents

Granting a longer term for pharmaceutical patents will result in delays in the entry of generic versions and could adversely affect access to medicines   By Feroz Ali, Live Mint | July 28, 2017 A proposal to further extend the … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

An Access Regime based on Indian Patents Act -Review Of “The Access Regime” by Feroz Ali

Source: LiveLaw.in Even though the Agreement on the trade-related aspects of intellectual property rights (TRIPS) set the minimum standards of protection and enforcement of intellectual property (IP) rights, it could not harmonise the various national patent laws. Irrespective of the … Continue reading

Posted in Compulsory Licensing, FTA, Patent Opposition, Sec 3 (d), TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

IP watch: UN human rights council adopts access to medicines resolution

Source: IP Watch | June 23, 2017 The United Nations Human Rights Council today adopted a resolution on the right to health in relation to the UN 2030 Sustainable Development Goals (SDGs), including a call for medicines and vaccines access for … Continue reading

Posted in High Level Panel, Transfer of Technology, TRIPS, TRIPS flexibilities, Uncategorized | Leave a comment

The Trump Executive Order on drug prices: not what was promised nor needed, and contrary to US self interest

Source: Medium Emily Kopp has a big scoop for Kaiser Health News. She has obtained a six page document outlining the draft provisions or objectives of a proposed Presidential Executive Order (EO) on drug prices. She has shared some of … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR Enforcement, Special 301 report, Uncategorized, UNHLP report, US Pressure | Leave a comment

June 2017 Alert: Pressure on countries hiked by US on IP

The US government is stepping up on TRIPS plus pressure through bilateral forums based on a US law that passed under Obama to strengthen IPR enforcement and the 301 process. Countries targeted include India, Indonesia, China, Thailand, Ukraine in Asia … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR Enforcement, Special 301 report, Uncategorized, UNHLP report, US Pressure | Leave a comment

TRIPS Council Members: Defining IP Rights And The Public Interest

Source: IPWatch “Political and economic pressure placed on governments to forgo the use of TRIPS flexibilities violates the integrity and legitimacy of the system of legal duties and rights created by the TRIPS agreement and as reaffirmed by the Doha … Continue reading

Posted in Compulsory Licensing, TRIPS, TRIPS flexibilities, Uncategorized | Leave a comment

FOIFOIA documents. In 2015 Novartis asked U.S. Dept of Commerce to Pressure Colombia Against Compulsory License on Glivec

In February 2016, KEI submitted a FOIA to USTR requesting “all correspondence and notes sent internally by the Office of the US Trade Representative as well as with Colombian government officials, other foreign government officials, and non-governmental persons or entities … Continue reading

Posted in Compulsory Licensing, Uncategorized | Leave a comment